Report #2862029

Received Sep 29, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: MD
Recovered: Unknown
Vaccinated: Feb 22, 2025
Onset: Sep 11, 2025
Days to onset: 201
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	2	—	IM / LA

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

Had First Dose 22-Feb-2025, Second Dose Received 11-Sep-2025; Initial report received on 11-Sep-2025. A consumer reported that he, a 28-year-old male, received the second dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization about six months after the first dose. No medical history or concomitant medications were reported. On 22-Feb-2025 the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC # not reported)] intramuscularly in the left upper arm. On 11-Sep-2025, approximately 6 months after having been vaccinated with dose 1 of HEPLISAV-B, the patient reported that they received dose 2 of HEPLISAV-B (lot # 945664, expiration date, NDC # 43528-0003-05) intramuscularly in the left upper arm. No side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.